Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15797501 | 0.84 | TSHR (0.59) | TP53SMN1; SMN2LMNAALDH1A1POLB | |
| SCHEMBL15797474 | 0.81 | SMN1; SMN2 (0.59) | TP53SMN1; SMN2LMNAALDH1A1TSHR | |
| SCHEMBL11928250 | 0.81 | ALDH1A1 (0.49) | SMN1; SMN2ALDH1A1POLBTSHR | |
| SCHEMBL6790327 | 0.80 | ALDH1A1 (0.68) | GAASMN1; SMN2LMNAALDH1A1TSHR | |
| SCHEMBL15797451 | 0.80 | LMNA (0.63) | MAPTTP53MEN1KMT2ALMNA | |
| SCHEMBL15797586 | 0.77 | TEAD1 (0.58) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL3159420 | 0.77 | OPRL1 (0.49) | MAPTTP53MEN1GAAKMT2A | |
| SCHEMBL15129556 | 0.75 | P2RX7 (0.48) | SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL15797662 | 0.75 | LMNA (0.54) | GAAKMT2ASMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL15797285 | 0.74 | ALDH1A1 (0.43) | MAPTTP53SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | BIOTIE THERAPIES CORP. (FI) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023735-A1 | Sulphonamide Derivatives | HCAR1, ADGRE5, ALK | MAPT 4881/4885TP53 4064/4885MEN1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.